Aarti Drugs Limited Overview
Aarti Drugs Limited is a mid-sized, backward-integrated Indian bulk-drug manufacturer whose core franchise is high-volume, mature generic Active Pharmaceutical Ingredients (APIs) across anti-infective, anti-protozoal, anti-diabetic, anti-inflammatory and anti-fungal therapies. The company claims global leadership in Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole and fluoroquinolones, and is a leading Metformin producer. APIs contributed 77% of FY2026 consolidated revenue of ₹2,568 crore, with formulations (largely export-led, via the company and its wholly owned subsidiary Pinnacle Life Science), specialty chemicals and intermediates making up the balance. Having completed a roughly ₹600 crore investment cycle — notably a methylamines backward-integration plant at Sayakha, Gujarat and a salicylic-acid plant at Tarapur — the company is now in a ramp-up phase aimed at restoring EBITDA margins to 13.5–14%, shifting mix toward regulated markets (73% of the relevant mix in FY2026) and reducing dependence on Chinese key starting materials.
Company's own description
In its FY2026–FY2027 investor releases, the company describes itself as a diversified and fully integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients, Formulations, Specialty Chemicals and Intermediates, which manufactures APIs, pharma intermediates and specialty chemicals and produces formulations through its wholly owned subsidiary Pinnacle Life Science Private Limited. Its investor presentations position it as a leading API producer with a portfolio of 50+ molecules spanning antibiotics, anti-protozoals, anti-inflammatories, anti-diabetics and anti-fungals, and state that it exports APIs and specialty chemicals to more than 100 countries.
Independent characterisation
Aarti Drugs is fundamentally a volume-driven, cost-competitive commodity-generic API manufacturer that has spent the last five years attempting to migrate up three ladders simultaneously:
-
Up the regulatory ladder — from semi-regulated/domestic API supply toward US/EU-registered APIs and export formulations (USFDA "VAI" status for its Tarapur E-22 API site in December 2024; regulated-market contribution rising from 66% in FY2025 to 73% in FY2026).
-
Down the value chain (backward integration) — internalising key starting materials and intermediates (methylamines at Sayakha for Metformin; salicylic acid at Tarapur; captive PTSCL and other chlorosulfonation chemistry), primarily to de-risk Chinese input dependence and protect margins.
-
Into adjacent businesses — formulations (including a USFDA-approved oncology formulation capability, per the Q1 FY2027 investor presentation) and specialty chemicals (benzene sulphonyl chloride, methyl nicotinate, salicylic acid and derivatives).
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales (bulk API, intermediates, specialty chemicals, finished formulations). No material service, subscription or licensing revenue disclosed. |
| Pricing | Largely spot/contract pricing for commodity APIs; realisations highly sensitive to Chinese supply and raw-material (crude-linked) costs. Management repeatedly cites "negative rate variance" in FY2024–FY2025 and "pricing pressure in select API segments" in FY2026. |
| Value-chain position | Mid-stream: converts basic/petrochemical feedstocks and intermediates into APIs; increasingly upstream (KSMs) and selectively downstream (formulations). |
| Customer types | Domestic and international formulation companies (generic manufacturers), specialty-chemical buyers, government/tender buyers for formulations (e.g., Chile via Pinnacle Chile SpA), and distributors. FY2025 BRSR states the company serves pharmaceutical formulation companies and specialty-chemical customers. |
| End-markets | Human generic pharmaceuticals (anti-infectives, anti-diabetics, analgesics/anti-inflammatories, anti-fungals, CNS e.g. Zolpidem, women's health e.g. Raloxifene), nutrition (Niacin), and industrial/specialty chemical users. |
| Reportable segment (Ind AS 108) | The company reports a single operating segment ("Pharmaceuticals"), with geographic segmentation of India vs Out of India (per MarketScreener summary of filings). Business-vertical revenue (API / Formulation / Specialty Chemicals / Intermediates & Others) is disclosed voluntarily in investor releases and is used throughout this dossier. |
Therapeutic mix within API (Q3 FY2026, company investor release)
| Therapeutic category | Share of API sales (%) |
|---|---|
| Antibiotics (incl. fluoroquinolones) | 35.1 |
| Anti-protozoal | 19.8 |
| Anti-diabetic | 16.6 |
| Anti-inflammatory | 12.9 |
| Anti-fungal | 12.2 |
| Others | 3.4 (derived) |
In Q1 FY2027 the antibiotic share was 35.0% (company investor release, 1 August 2026), indicating a stable mix.
Strategy
Stated strategic themes (company releases, FY2026–FY2027)
Backward integration and input security: Investments in methylamines (Sayakha) and salicylic acid (Tarapur) to strengthen margin performance and reduce exposure to raw-material volatility.
Regulated-market pivot: Prioritising US and EU regulatory filings and approvals, which management expects to open margin-expansion opportunities.
Export formulations as a value driver: Management expects the formulations business to become a primary value driver, citing strong export traction.
Downstream specialty chemicals: A salicylates line downstream of salicylic acid is being implemented, which management believes can transform the specialty-chemicals vertical.
- Operational efficiency and capacity enhancement, alongside disciplined procurement (Q1 FY2027 CFO commentary).
Governance continuity: The 2026 leadership transition was explicitly framed as not altering long-term strategic direction.
Initiative register (last 24 months)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Sayakha greenfield (methylamines) | Trial Jul 2025; commercial 4 Sep 2025 | Target >800 t/month, installed ~1,600 t/month by end FY2026 (stated Jul 2025); ~1,000 t/month achieved Mar 2026; 65% utilisation Q1 FY2027 | Ramping; brief GPCB closure Jul 2026, revoked |
| Tarapur salicylic-acid greenfield | Expected contribution from Q3 FY2026 | >300 t/month achieved early 2026 | Ramping |
| Salicylates downstream line | Announced Feb 2026 | Under implementation | In progress |
| Tarapur API expansion | Jul 2025 commentary | More production blocks planned at USFDA-approved site; new regulated-customer audits triggered | Planned |
| Brownfield programme | May 2026 | ₹300–400 crore over coming years | Planned |
| Chile market entry | Nov 2024 / Mar 2026 | Pinnacle Chile SpA; Tripharma Chile SpA | Operational/early |
| Pinnacle recapitalisation | Mar 2026 | ₹10 crore equity infusion | Completed |
| Shareholder returns | Aug–Sep 2024; Feb 2026 | ₹59.85 crore buyback; doubled interim dividend to ₹2 | Completed |
| Investor engagement | May–Jun 2026 | Analyst meets with 360 ONE Capital (27 May) and Choice Institutional Equities (10 Jun) | Completed |
ESG/sustainability commitments
BRSR filed for FY2025 and FY2026. Specific quantified emissions targets were not publicly disclosed in retrieved sources. Post-GPCB, the company stated it is implementing corrective and preventive measures to avoid future lapses.
Medium-term guidance
| Metric | Guidance | Source |
|---|---|---|
| FY2027 EBITDA margin | 13.5%–14% (despite higher crude prices and West Asia uncertainty) | Q4 FY2026 call (FilingReader, 23 May 2026) |
| Brownfield capex | ₹300–400 crore over coming years | Q4 FY2026 call |
| Medium-term capex (rating-agency view) | ₹150–200 crore p.a. | CRISIL, Jan 2026 |
| Revenue growth target | — | — |
Products & Services
The company does not publish a priced catalogue; the following is assembled from regulatory disclosures, investor presentations and company statements. Launch years and pricing are not publicly disclosed unless noted.
APIs (50+ molecules)
| Product | Therapy | Notes / capabilities | Source |
|---|---|---|---|
| Metformin HCl | Anti-diabetic | Among the world's leading producers (company profile); Sayakha methylamines plant built to backward-integrate Metformin | Groww company profile; Sahi summary of GPCB filing |
| Nimesulide | Anti-inflammatory | Company claims largest global producer | AGM 2026 presentation |
| Ketoconazole | Anti-fungal | Company claims largest global producer | AGM 2026 presentation |
| Metronidazole / Metronidazole Benzoate | Anti-protozoal | Company claims largest global producer of the benzoate; largest Metronidazole producer in India | AGM 2026 presentation; Groww profile |
| Tinidazole | Anti-protozoal | Company claims largest global producer | AGM 2026 presentation |
| Fluoroquinolones (incl. Ciprofloxacin HCl; others such as Ofloxacin/Norfloxacin — individual molecules not re-verified) | Antibiotic | Company claims global leadership in fluoroquinolones; Ciprofloxacin HCl cleared for US supply post-EIR | AGM 2026 presentation; Dec 2024 EIR disclosure |
| Zolpidem Tartrate | CNS (hypnotic) | US-market supply enabled after Dec 2024 EIR | Company disclosure |
| Raloxifene HCl | Women's health (osteoporosis) | US-market supply enabled | Company disclosure |
| Celecoxib | Anti-inflammatory (COX-2) | US-market supply enabled | Company disclosure |
| Niacin | Vitamin / lipid | US-market supply enabled | Company disclosure |
Formulations
| Offering | Description | Source |
|---|---|---|
| Export formulations | 65% of FY2026 standalone formulation sales were exports (74% in Q1 FY2027); strong growth into regulated markets | FY2026 and Q1 FY2027 releases |
| Oncology formulations | USFDA-approved oncology formulation capability | Q1 FY2027 investor presentation |
| Pinnacle Life Science | Wholly owned formulation subsidiary (domestic and export); recapitalised with ₹10 crore in March 2026 | Company filings |
| Chile tender business | Pinnacle Chile SpA / Tripharma Chile SpA for Chilean public tenders and private market | FY2025 Directors' Report; Mar 2026 filing |
Specialty chemicals & intermediates
| Product | Description | Source |
|---|---|---|
| Benzene sulphonyl chloride | Specialty chemical (sulphonation/chlorosulphonation chemistry) | MarketScreener company description |
| Methyl nicotinate | Specialty chemical | MarketScreener company description |
| PTSCL (para-toluene sulphonyl chloride) | Captive and merchant sale; chlorosulfonation at T-150, Tarapur (paused Sept 2025 after HCl leak) | Company filing, Sept 2025 |
| Methylamines (Sayakha, Gujarat) | Backward integration for Metformin; commercial production 4 Sep 2025; ~1,000 t/month by Mar 2026; 65% utilisation in Q1 FY2027 | Company releases; Quartr Q1 FY2027 summary |
| Salicylic acid (Tarapur greenfield) | Scaled to >300 t/month by early 2026; downstream salicylates line under implementation | Q3 FY2026 commentary |
| NCB-based specialty chemicals | Company noted for strong position in nitrochlorobenzene-based chemistry (aggregator characterisation) | AlphaStreet profile |
Financial Narrative
Income statement (consolidated, ₹ crore)
Sources: Revenue, gross profit and interest — StockAnalysis (converted from INR millions); EBITDA, PBT, PAT — Anand Rathi summary of reported results; FY2026 cross-checked to company release (revenue ₹2,567.7 crore total revenue; EBITDA ₹311.6 crore; PBT ₹210.9 crore; PAT ₹194.9 crore). Company-defined FY2026 gross profit is ₹949.0 crore (FY2025: ₹861.3 crore), which differs from the aggregator definition shown.
(derived from table above; company reports FY2026 EBITDA margin 12.1% and PAT margin 7.6%, FY2025 12.6% and 7.0%)
Sources: Company FY2026 release (EPS); FY2025 Directors' Report (₹1 interim); Feb 2026 filing (₹2 interim). Basic and diluted EPS are identical (no dilutive instruments disclosed). Dividends of ~₹9.2 crore (≈₹1/share) are referenced by ICRA for the FY2024 period.
Revenue CAGR FY2022–FY2026: 0.8% (derived). PAT CAGR FY2022–FY2026: −1.3% (derived). Screener's machine summary similarly flags weak five-year sales growth.
Commentary. The five-year picture is one of stagnation followed by a tentative recovery. Revenue peaked in FY2023 at ₹2,716 crore on the back of ~10% API price increases, then fell 6.9% in FY2024 and 5.6% in FY2025 as post-COVID industry overcapacity and Chinese price competition drove "negative rate variance" — the company's own Q1 FY2027 presentation attributes post-COVID revenue weakness to industry-wide oversupply and sharp API price erosion. Gross margin (aggregator basis) actually expanded from ~30% to ~37% over the period as input costs fell faster than realisations, but this was absorbed by rising operating costs (other operating expenses rose from ₹364 crore to ₹506 crore, per StockAnalysis) and new-plant start-up costs, keeping EBITDA margin in an 11–14% band. FY2026 PAT growth of 16% outpaced EBITDA growth of 3% largely because of a low effective tax rate (PAT ₹194.9 crore on PBT ₹210.9 crore), including a ~₹15 crore principal tax refund booked in Q1 FY2026 — so FY2026's earnings quality is somewhat flattered.
Quarterly trajectory (consolidated, ₹ crore)
Sources: Company quarterly releases. Q2 FY2026 EBITDA and PAT (derived from 9M FY2026 EBITDA ₹215.0 crore and PAT ₹139.7 crore). Q1/Q2 FY2026 PBT (derived from FY2026 PBT and Q3/Q4 actuals and Q1 FY2027's +35% YoY PBT growth implying Q1 FY2026 PBT of ~₹51.1 crore). Q1 FY2027 EBITDA/PBT/PAT include ~₹2 crore CWIP write-off; Q1 FY2026 PAT includes ~₹15 crore tax refund.
Commentary. The Q3 FY2026 trough (9.3% EBITDA margin) coincided with Sayakha's initial scale-up costs; the subsequent two quarters at 13.4–13.8% suggest the company is approaching management's FY2027 margin target of 13.5–14%. On a like-for-like basis (excluding the Q1 FY2026 tax refund), Q1 FY2027 PAT rose meaningfully rather than falling 7%.
Balance sheet (selected, ₹ crore)
Sources: ICRA rationales (Mar 2022 and Mar 2025 balance-sheet dates). CRISIL cites ₹612 crore at 31 Mar 2025 — minor discrepancy with ICRA's ₹615.1 crore, both noted.
Additional verified balance-sheet data points (not available for all five years):
Goodwill & intangibles and a full working-capital breakdown are not publicly disclosed in retrieved sources (the company is asset-heavy with negligible acquired goodwill; no material acquisitions identified). Net debt at 30 Sep 2025 was approximately ₹561–564 crore (derived).
Commentary. Leverage rose through the capex cycle (cumulative ~₹600 crore per ICRA) — total debt/OPBDITA drifted from 1.6x to 2.1–2.2x — but working-capital release brought debt down by ~₹40 crore in H1 FY2026. Liquidity is managed through large working-capital lines rather than cash balances (cash of under ₹10 crore against ₹1,085 crore of short-term limits), a typical Indian mid-cap API structure. CRISIL expects ~₹220 crore of annual cash accrual against term-debt obligations of ₹40–70 crore and capex of ₹150–200 crore per annum — i.e., limited free cash after capex and buybacks.
Cash flow
Commentary. Capital allocation has been notably shareholder-friendly for a company of this size, with four tender buybacks in seven years, while dividends have remained token (Screener notes a ~5% payout over three years). This pattern — buybacks favoured over dividends — reflects Indian tax considerations and promoter participation choices.
Ratios
Commentary. Returns have compressed from the COVID-era peak (FY2021 PAT ₹280 crore) to low-teens ROE, with ROCE of 11.5% in FY2026 sitting close to a reasonable cost of capital — the capex cycle has diluted returns pending ramp-up. Interest coverage halved between FY2022 and FY2023 as debt and rates rose, but has been stable since.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Function | Source |
|---|---|---|---|
Aarti Drugs Limited | Listed parent | APIs, intermediates, specialty chemicals, standalone formulations; contributed 89% of consolidated revenue in Q1 FY2027 | Q1 FY2027 release |
Pinnacle Life Science Private Limited | 100% subsidiary | Finished-dosage formulations | FY2025 BRSR; company releases |
Aarti Speciality Chemicals Limited | 100% subsidiary | Specialty chemicals vehicle | FY2025 BRSR |
Pinnacle Chile SpA | Subsidiary (incorporated 27 Nov 2024) | Marketing formulations; Chilean tenders and private market | FY2025 Directors' Report |
Tripharma Chile SpA | Step-down subsidiary (incorporated 2 Mar 2026) | Chilean market expansion (precise scope not disclosed) | Company filing summary |
Revenue by Segment
| Segment (INR Cr, consolidated) | FY2025 | FY2026 |
|---|---|---|
API | 1,938.4 | 1,979.4 |
Formulations | 248.9 | 331.2 |
Specialty Chemicals | 130.0 | 178.3 |
Intermediates & Others | 69.4 | 76.4 |
Total revenue from operations | 2,386.7 | 2,565.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2025 | FY2026 |
|---|---|---|
API | 81.2 | 77.2 |
Formulations | 10.4 | 12.9 |
Specialty Chemicals | 5.4 | 7.0 |
Intermediates & Others | 2.9 | 3.0 |
Segment YoY growth (%)
| Segment YoY growth (%) | FY2026 |
|---|---|
API | 2 |
Formulations | 33 |
Specialty Chemicals | 37 |
Intermediates & Others | 10 |
Revenue by Segment (Quarterly)
| Segment (INR Cr) | Q4FY2025 | Q3FY2026 | Q4FY2026 | Q1FY2026 | Q1FY2027 |
|---|---|---|---|---|---|
API | 553.1 | 454.3 | 551.0 | 458.2 | 510.4 |
Formulations | 64.8 | 76.4 | 92.0 | 80.3 | 86.2 |
Specialty Chemicals | 39.0 | 51.1 | 56.8 | 33.1 | 82.6 |
Income Statement
| Metric (INR Cr, consolidated) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 2,488.6 | 2,716.1 | 2,528.6 | 2,387.0 | 2,565.3 |
Gross profit (aggregator definition) | 786.5 | 805.8 | 831.6 | 825.6 | 946.6 |
EBITDA (operating profit) | 340.8 | 307.8 | 320.5 | 303.4 | 311.6 |
Interest expense | 20.7 | 33.3 | 33.5 | 35.9 | 33.7 |
Profit before tax | 270.0 | 224.2 | 235.5 | 211.8 | 210.9 |
Net profit (PAT) | 205.0 | 166.4 | 171.6 | 168.1 | 194.9 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (aggregator definition) | 31.6 | 29.7 | 32.9 | 34.6 | 36.9 |
EBITDA margin | 13.7 | 11.3 | 12.7 | 12.7 | 12.1 |
PBT margin | 10.8 | 8.3 | 9.3 | 8.9 | 8.2 |
Net margin | 8.2 | 6.1 | 6.8 | 7.0 | 7.6 |
Per-share data (INR)
| Per-share data (INR) | FY2025 | FY2026 |
|---|---|---|
EPS basic/diluted (consolidated) | 18.44 | 21.36 |
Dividend per share | 1 | 2 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|
Total revenue | 590.8 | 652.9 | 602.9 | 721.1 | 703.6 |
EBITDA | 74.4 | 84.3 | 56.3 | 96.6 | 96.9 |
EBITDA margin (%) | 12.6 | 12.9 | 9.3 | 13.4 | 13.8 |
PBT | 51.1 | 60.4 | 29.0 | 70.4 | 69.2 |
PAT | 54.0 | 45.2 | 40.5 | 55.3 | 50.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials
| Metric (INR Cr) | FY2022 | FY2025 |
|---|---|---|
Total debt (consolidated) | 542.8 | 615.1 |
Data Point Details
| Data point | Value | Date | Source |
|---|---|---|---|
Total debt | ₹589.1 crore | 30 Sep 2023 | ICRA |
Total debt | ₹596.5 crore | 31 Dec 2023 | ICRA |
Total debt | ₹590.1 crore | 30 Sep 2024 | ICRA |
Total debt | ₹571 crore (CRISIL) / ₹573.5 crore (ICRA) | 30 Sep 2025 | CRISIL Jan 2026; ICRA Mar 2026 |
Cash & equivalents (unencumbered, incl. investments) | ₹9.57 crore | 30 Sep 2025 | CRISIL Jan 2026 |
Gearing (debt/equity) | 0.39x | 30 Sep 2025 | CRISIL Jan 2026 |
Total debt / OPBDITA | 1.6x (Mar 2022); 1.8x (Mar 2023); 2.1x (Mar 2025); 2.2x (Sep 2024) | various | ICRA |
Net worth | ₹1,549 crore | 31 Mar 2026 | AGM 2026 presentation |
Book value per share | ~₹154–161 | 2026 | Screener / Groww (data-date dependent) |
Rated bank facilities | ₹1,452.80 crore (ICRA); ₹1,768 crore (CRISIL) | Mar 2026 / Jan 2026 | Rating rationales |
Short-term fund/non-fund-based limits | ₹1,085 crore | Mar 2026 | ICRA |
Term loans rated | ₹253.13 crore (+₹49.67 crore proposed) | Mar 2026 | ICRA |
Regulated-market contribution | 66% → 73% | FY2025 → FY2026 | FY2026 results release |
Formulation exports share (standalone) | 65% | FY2026 | FY2026 release |
Formulation exports share | 69% | Q4 FY2026 | FY2026 release |
Formulation exports share | 74% | Q1 FY2027 | Q1 FY2027 release |
Formulation exports share | 53% | Q2 FY2025 | Q2 FY2025 earnings call |
Formulation exports share (9M) | 64% | 9M FY2026 | Q3 FY2026 release |
Domestic revenue growth | +25% YoY | Q1 FY2027 | Q1 FY2027 release |
Export revenue growth | +12% YoY | Q1 FY2027 | Q1 FY2027 release |
Countries served | 100+ | 2026 | AGM 2026 presentation |
Formulation export share (%) | Q2FY2025 | Q4FY2026 | Q1FY2027 |
Exports as % of formulation revenue | 53 | 69 | 74 |
Financial Analysis
| Metric | Disclosure status |
|---|---|
Operating cash flow (5 years) | Not publicly disclosed in retrieved sources |
Capex | ~₹220–230 crore expected FY2024 and FY2025 (ICRA 2024); ~₹150 crore expected FY2026 (ICRA 2026); ₹150–200 crore p.a. medium term (CRISIL); ₹300–400 crore brownfield programme announced May 2026 |
Dividends paid | ~₹9.1–9.2 crore p.a. at ₹1/share (FY2024–FY2025); ~₹18.3 crore at ₹2/share (FY2026, derived) |
Buybacks | FY2018 ~₹24.1 crore; FY2021 up to ₹60 crore; FY2023–24 ~₹60 crore (₹73.2 crore incl. tax); FY2025 ₹59.85 crore |
Financial Analysis — ROCE
| Ratio | Value | Period | Source |
|---|---|---|---|
ROCE | 11.5% | FY2026 | AGM 2026 presentation |
ROE | ~12.7–13.6% | TTM 2026 | Screener; Groww |
Debt/equity | 0.39x | Sep 2025 / 2026 | CRISIL; Groww |
Total debt / OPBDITA | 2.1x | Mar 2025 | ICRA |
Interest coverage (EBITDA/interest) | 9.2x | FY2026 (derived) | — |
Interest coverage (EBITDA/interest) | 16.5x | FY2022 (derived) | — |
ROA, ROIC, current ratio, asset turnover, cash conversion cycle | Not publicly disclosed in retrieved sources | — | — |
Ratio | FY2022 | FY2023 | FY2024 |
EBITDA / interest (x, derived) | 16.5 | 9.2 | 9.6 |
Valuation Snapshot
| Metric | Value | Date | Source |
|---|---|---|---|
Share price (NSE) | ₹415 | 5 Oct 2026 | IIFL |
Market capitalisation | ₹3,787.7 crore | 5 Oct 2026 | IIFL |
52-week range | ₹318.95 – ₹534 | As of 5 Oct 2026 | IIFL |
P/E | 22.3x (reported basis) | 5 Oct 2026 | IIFL |
P/E on TTM consolidated PAT | ~19.8x (derived; TTM PAT ₹191.0 crore) | Oct 2026 | — |
P/B | 2.74x | 5 Oct 2026 | IIFL |
EV (approx.) | ~₹4,380 crore (derived: market cap + ~₹600 crore debt − ~₹10 crore cash) | Oct 2026 | — |
EV/EBITDA (FY2026) | ~14.1x (derived) | — | — |
EV/EBITDA (TTM, EBITDA ₹334.1 crore) | ~13.1x (derived) | — | — |
EV/Sales (TTM revenue ₹2,677.6 crore) | ~1.6x (derived) | — | — |
1-year share-price return | ~−8% | Oct 2026 | IIFL |
Share price checkpoints (INR) | Jun2026 | Jul2026 | Aug2026 |
Closing price | 370 | 424 | 418 |
Dividend per share (INR)
| Dividend per share (INR) | FY2025 | FY2026 |
|---|---|---|
Interim dividend | 1 | 2 |
Capital Programmes
| Programme | Price (₹/share) | Size | Shares | Source |
|---|---|---|---|---|
Jan 2018 | 875 | ~₹24.1 crore | ~0.27 million | Business Standard |
Mar 2021 | 1,000 | Up to ₹60 crore | Up to 0.6 million | Business Standard |
FY2023–FY2024 | — | ~₹60 crore (₹73.2 crore incl. tax) | — | ICRA |
Aug–Sep 2024 | 900 | ₹59.85 crore | 0.665 million (0.72%) | BSE filing; NSE circular |
Credit Ratings
| Agency | Long-term | Short-term | Outlook | Amount rated | Date |
|---|---|---|---|---|---|
ICRA | [ICRA]AA- | [ICRA]A1+ | Stable | ₹1,452.80 crore | 24 Mar 2026 |
CRISIL | Crisil AA- | Crisil A1+ | Stable | ₹1,768 crore | 28 Jan 2026 |
Moody's / S&P / Fitch | Not rated | — | — | — | — |
Analyst Conclusions
Management guidance
-
FY2027 EBITDA margin of 13.5%–14% (Q1 FY2027 delivered 13.8%).
-
Continued ramp-up of Sayakha (65% utilisation in Q1 FY2027) and salicylic acid, with salicylates downstream line under implementation.
-
₹300–400 crore brownfield capex over coming years; priority on US/EU filings.
-
Encouraging demand outlook across APIs, specialty chemicals and formulations (Q1 FY2027 CFO commentary).
Consensus expectations
Not publicly available (no verified consensus).
Bull case
-
Margin inflection is underway: EBITDA margin moved from 9.3% (Q3 FY2026) to 13.8% (Q1 FY2027); sustaining 14% on ~₹2,800 crore revenue would imply EBITDA of ~₹390 crore vs ₹311.6 crore in FY2026 (analyst illustration, not guidance).
-
Diversified growth engines: Specialty chemicals (+150% YoY in Q1 FY2027) and export formulations (74% export share) are compounding off small bases and carry better pricing power than commodity APIs.
-
Overhangs removed and balance sheet sound: Supreme Court dismissal of the ₹251 crore GST claim, GPCB revocation within two weeks, and AA- ratings with 0.39x gearing reduce tail risks at an undemanding ~13x TTM EV/EBITDA.
Bear case
-
Structural commodity exposure: API (77% of revenue) grew only 2% in FY2026; any renewed Chinese price aggression can erase backward-integration gains, as FY2024–FY2025 demonstrated.
-
EHS pattern risk: Three pollution-board actions in two years; a prolonged closure at Sayakha or Tarapur would hit both cost structure and the regulated-customer narrative.
-
Capital intensity vs returns: ROCE of 11.5% after ~₹600 crore of capex, with a further ₹300–400 crore planned, risks value-neutral growth if utilisation and pricing disappoint; thin cash and buyback-heavy allocation leave limited buffer.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q2 FY2027 results | Expected late Oct–mid Nov 2026 (date unconfirmed) | Margin sustainability ≥13.5%; Sayakha utilisation post-GPCB |
| New leadership's first strategic communication | H2 FY2027 | Capital-allocation framework; CFO appointment |
| USFDA/EU inspections and approvals | Ongoing | Any Form 483s; new DMF/CEP approvals |
| Salicylates line commissioning | FY2027 (timing not disclosed) | Revenue contribution |
| Brownfield capex execution | FY2027–FY2028 | Debt trajectory vs ~₹220 crore accrual |
| EHS compliance | Ongoing | Any further MPCB/GPCB actions; PTSCL resumption |
| API price environment | Ongoing | China export pricing for metformin, metronidazole, fluoroquinolones |
| Rating surveillance | ICRA due by Mar 2027 | Outlook stability |
Analyst verdict
Aarti Drugs enters FY2027 in a better position than at any point since the post-COVID API downcycle began. The heavy lifting of its investment cycle is done: the Sayakha methylamines plant is producing at scale, the Tarapur salicylic-acid plant is ramping, the Tarapur API site holds USFDA VAI status, and two of the three most visible overhangs of the past year — the ₹251 crore GST dispute and the Sayakha closure order — have been resolved in its favour within weeks of each other. Q1 FY2027's 19% revenue growth and 13.8% EBITDA margin suggest that management's 13.5–14% FY2027 margin target is achievable, and the stock, at roughly 20x trailing earnings and 13x EV/EBITDA, does not price in a sustained recovery.
Yet the investment case remains that of a cyclical, commodity-API producer attempting a structural re-rating, and the evidence for the structural part is still early. API revenue — over three-quarters of the business — grew just 2% in FY2026; return on capital (11.5%) has not yet responded to the ₹600 crore deployed; and the EHS record, with three pollution-board interventions in two years, is inconsistent with a company courting Western regulated customers. The October 2026 leadership transition consolidates authority under Rashesh Gogri, who brings group-wide chemistry depth but also carries simultaneous top roles at two other listed Aarti companies.
Our synthesis: the near-term earnings trajectory is favourable and downside appears cushioned by valuation, credit quality and resolved legal overhangs, but a durable re-rating requires (i) two to three more quarters of 13.5%+ margins without one-offs, (ii) visible growth in API volumes into regulated markets, and (iii) an incident-free EHS record. Absent those, Aarti Drugs is best viewed as a well-managed cyclical recovery play rather than a compounding franchise.
SOURCE LIST (primary and secondary documents consulted)
-
Company investor releases and presentations: Q1 FY2026 (Jul 2025), Q3 FY2026 (Feb 2026), Q4/FY2026 (May 2026), Q1 FY2027 (1 Aug 2026) — NSE/BSE archives
-
Company Regulation 30 filings: GST litigation (6 Oct 2025; 16 Mar 2026; 10 Aug 2026); GPCB closure and revocation (18 Jul 2026; 1 Aug 2026); MPCB orders (17 Jul 2024; 7 Aug 2024; Sep 2025); leadership transition (31 Jul 2026); credit rating (24 Mar 2026); buyback (Aug 2024)
-
FY2025 Directors' Report (via IIFL); FY2025 BRSR (NSE)
-
ICRA rating rationales (2024, Mar 2026); CRISIL rating rationale (28 Jan 2026)
-
NSE circular CMTR63946 (Sep 2024)
-
Aggregators: StockAnalysis, Anand Rathi, Screener, IIFL, Groww, Choice India, Finology Ticker, share.market, 5paisa, MarketScreener, Quartr
-
News: Indian Pharma Post, Business Standard, FilingReader, ScanX, Medical Dialogues, Sahi, Multibagg, Investywise
-
Peer data: IOL Chemicals & Pharmaceuticals Q4 FY2026 and Q1 FY2027 releases; Aarti Pharmalabs results (Anand Rathi)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / background | Source |
|---|---|---|---|
Rashesh C. Gogri | Chairman & Managing Director | MD since Sep 2014 (previously Whole-time Director); 27+ years in production, marketing and project implementation in chemicals/pharma; also Vice Chairman & MD of Aarti Industries Ltd and Chairman of Aarti Pharmalabs Ltd. Promoter. Chairman from 1 Oct 2026 | Company press release, 31 Jul 2026 |
Adhish P. Patil (DIN 02629496) | Managing Director (5-year term from 1 Oct 2026, subject to shareholder approval at AGM) | Previously CFO & COO. Sources conflict on tenure: CNBC-TV18 cites 25+ years of association; the company press release references "over a decade" — discrepancy noted | Company filing; CNBC-TV18 via AskFuzz |
Harshit M. Savla | Joint Managing Director (re-appointed) | Promoter-group executive | CNBC-TV18 summary of board outcome |
Harit P. Shah | Whole-time Director (re-appointed) | Participated in earnings calls (Q2 FY2025) | Board outcome; Q2 FY2025 call |
Prakash M. Patil (DIN 00005618) | Former Chairman, MD & CEO (retired 30 Sep 2026; advisory role continues) | Associated since inception; Chairman since 2014 | Company press release |
Uday M. Patil | Former Whole-time Director | Ceased; did not seek re-appointment | Board outcome, 31 Jul 2026 |
CFO (successor to Adhish Patil) | Not publicly disclosed in retrieved sources | — | — |
Governance Overview
| Feature | Detail | Source |
|---|---|---|
Chair/CEO separation | No — Chairman has been an Executive Director (FY2025 Directors' Report); from 1 Oct 2026 the Chairman is also MD (executive chair) | FY2025 Directors' Report; Jul 2026 filing |
Independent directors (named in retrieved filings) | Salvi (added to Risk Management Committee, May 2026) | FY2025 Directors' Report; board outcomes |
Committees | Audit; Nomination & Remuneration (recommended the 2026 transition); Risk Management (re-constituted May 2026 and Oct 2026); others re-constituted effective 1 Oct 2026 | Company filings |
Board-level independence % | Not publicly disclosed in retrieved sources (SEBI LODR requires at least 50% independent directors where the Chairman is executive) | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Jul 2026 (approved) / 1 Oct 2026 (effective) | Prakash M. Patil retires; Rashesh Gogri becomes Chairman; Adhish Patil becomes MD; Uday Patil ceases as WTD; Harshit Savla and Harit Shah re-appointed | Described by company as an orderly succession; no change to strategy |
15 May 2026 | Risk Management Committee re-constituted | Governance refresh |
9 May 2025 | Two independent directors re-appointed for second terms | Postal ballot / AGM approvals |
Shareholding Trend
| Holder category | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoter & promoter group (%) | 55.48 | 55.22 | 54.72 | 55.03 | 54.43 |
Governance Detail
| Data point | Value | Source |
|---|---|---|
Promoter pledge | 2.50% (Jun 2026); 2.47% (Mar 2026) | Finology Ticker |
Mutual funds | 9.81% (Sep 2025) | Choice India |
FIIs | 2.68% (Sep 2025); ~1.5% (Aug 2026, per share.market) | Choice India; share.market |
Retail | ~32.7% (Sep 2025) | Choice India |
Top 10 institutional holders with stakes | Not publicly disclosed in retrieved sources | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlap | Relative positioning |
|---|---|---|---|
Bulk APIs (anti-diabetic, analgesics) | IOL Chemicals & Pharmaceuticals | Metformin and other high-volume APIs; also specialty chemicals | Comparable scale; faster recent growth |
Bulk APIs | Granules India | Metformin, paracetamol and high-volume APIs; vertically integrated into formulations | — |
Bulk APIs / intermediates | Aarti Pharmalabs (group company) | APIs, xanthine derivatives, intermediates | Higher margin; sister company under common chairman |
APIs | Solara Active Pharma Sciences | Generic APIs for regulated markets | Turnaround story; smaller |
APIs (anti-infective, anti-diabetic) | Wanbury | Metformin | Smaller |
APIs (fluoroquinolones, anti-infectives) | Large integrated Indian generics (e.g., Aurobindo, Lupin — captive API) | Ciprofloxacin and similar molecules | Captive consumers and occasional competitors |
APIs (all categories) | Chinese bulk-drug manufacturers (Shandong/Zhejiang/Hubei clusters) | Metformin, metronidazole, fluoroquinolones, ketoconazole | Principal price-setters; drive realisation cycles |
Methylamines (specialty chemicals) | Balaji Amines; Alkyl Amines Chemicals | Methylamines | Established merchant producers; Aarti's Sayakha output is primarily captive |
Specialty chemicals (benzene chemistry) | Aarti Industries (group company) and other benzene-chain producers | NCB/sulphonation chemistry | Group overlap rather than direct competition |
Formulations (exports) | Mid-sized Indian export formulators (e.g., Alembic, Unichem, Indoco — illustrative) | Generic dosage forms in regulated/tender markets | Aarti is sub-scale in formulations |
Peer Comparison FY2026
| Metric (FY2026, INR Cr) | Aarti Drugs | IOL Chemicals & Pharma | Aarti Pharmalabs |
|---|---|---|---|
Revenue from operations | 2,565.3 | 2,319.1 | 1,819.4 |
EBITDA | 311.6 | 290.4 | 379.0 |
EBITDA margin (%) | 12.1 | 12.5 | 20.8 |
PAT | 194.9 | 137.7 | 166.7 |
Revenue growth FY2026 (%) | 7 | 16 | — |
Competitor Detail
| Q1 FY2027 comparison | Aarti Drugs | IOL Chemicals & Pharma |
|---|---|---|
Revenue (INR Cr) | 702.8 | 756.3 |
Revenue growth YoY (%) | 19 | 37 |
EBITDA margin (%) | 13.8 | 14.6 |



